Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3063)	1/12/2014 10:48:22 AM
From: Jibacoa	Respond to of 3722

CYTK has been among the good movers this year.<g> It was up another 14.73% on Friday, on volume of > 1.6M <g> The stock has been trying to close its Sep. DG.<g> bigcharts.marketwatch.com And with some good news, it seems that it has plenty of room to run upstairs. <g> . bigcharts.marketwatch.com On Friday CYTK announced the results from a first-time-in-humans clinical trial of its CK-2127107 in healthy male volunteers which were presented at the 7th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders in Kobe, Japan. CK-2127107 and other skeletal sarcomere activators have demonstrated pharmacological activity that may lead to new therapeutic options for diseases associated with aging and muscle wasting. The clinical effects of muscle wasting, fatigue and loss of mobility can range from decreased quality of life to life-threatening complications. By directly improving skeletal muscle function, a small molecule activator of the skeletal sarcomere may potentially enhance physical performance and quality of life in patients with conditions marked by muscle weakness and fatigue. <g> Bernard